News for Twist Bioscience Corporation (TWST)

[url="]Twist Bioscience Corporation[/url] (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today annou

We recently compiled a list of the Cathie Wood's Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a look at where Twist Bioscience Corporation (NASDAQ:TWST) stands against the...

Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Twist Bioscience reported solid Q1 FY25 results, although this was insufficient to drive the company's share price higher. Read why TWST stock is a Hold.

Earnings Call Insights: Twist Bioscience Corporation (NASDAQ:TWST) Q1 2025Management ViewCEO Emily Leproust highlighted record revenue of $88.7 million for...

Twist Bioscience Corporation (NASDAQ:TWST) Q1 2025 Earnings Conference Call February 3, 2025 8:00 AM ETCompany ParticipantsAngela Bitting - Senior Vice...

Twist Bioscience (TWST) delivered earnings and revenue surprises of 14.52% and 2.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

[url="]Twist Bioscience Corporation[/url] (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector

The following slide deck was published by Twist Bioscience Corporation in conjunction with their 2025 Q1 earnings call.

Twist Bioscience director Robert Chess sells $250,000 in stock

Twist Bioscience (TWST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

After losing some value lately, a hammer chart pattern has been formed for Twist Bioscience (TWST), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers.

Ark Invest chief Cathie Wood is known for scooping up shares of innovators early in their growth stories and holding on for the long term. This takes time, but patient investors could score a major win by following Wood's strategy -- and by picking up a couple of her favorite stocks. Over the past several weeks, Wood has added to one of her key positions, a stock that's lost about 20% this year.

Twist Bioscience's SynBio and NGS segments continue to generate strong growth, despite macro challenges.

Cathie Wood's ARK ETF shifts focus with major stock trades in AMD and TER

Cathie Wood's ARK buys Teradyne and Ibotta, sells Tesla and Palantir stock